We have previously identified several novel genes, which are differentially expressed among human normal liver and hepatocellular carcinomas (HCCs). The full-length liver fibrinogen-related gene-1 (LFIRE-1) cDNA was cloned from the human normal liver cDNA library. LFIRE-1 is highly homologous to HFREP-1 with discrepancy at 5 0 untranslated region (UTR) and encodes the same fibrinogen-related protein, which suggest that these two sequences might be alternative splicing forms of the same gene, LFIRE-1/HFREP-1, located at human chromosome 8p22. The LFIRE-1 and HFREP-1 are specifically expressed in normal human liver tissue, but reduced or undetectable in most of HCC specimens at both RNA and protein level. Furthermore, the reduction or nonexpression of LFIRE-1/HFREP-1 is significantly associated with the degree of tumor differentiation. Loss of heterozygosity (LOH) analysis revealed allelic loss of LFIRE-1/HFREP-1 on chromosome 8p22 in 57.1% (24/ 42) of HCC specimens. We detected three inactivation mutations among 45 cases of HCC specimens examined, two of which lost the remaining allele and the third had a replacement of conserved cysteine residue with glycine residue. Notably, the downregulation of LFIRE-1/ HFREP-1 expression is frequently associated with allelic loss. The reduction of LFIRE-1/HFREP-1 expression by antisense approach enhances cancer cell proliferation and colony formation in soft agar. Moreover, restoration of exogenous wild-type LFIRE-1/HFREP-1 expression but not LFIRE-1/HFREP-1 missense mutations in human HCC cells inhibited their anchorage-dependent orindependent growth in vitro, and suppressed their tumorigenicity in nude mice. In conclusion, our data demonstrated that liver-specific gene LFIRE-1/HFREP-1 was frequently downregulated and might possess growth suppressor activity in HCC. Oncogene (2004) 23, 1939-1949. doi:10.1038/sj.onc.1207306 Published online 23 February 2004 Keywords: Hepatocellular carcinoma (HCC); 8p22; fibrinogen-related domain; liver-specific expression; differentiation
Introduction
Human primary hepatocellular carcinoma (HCC) ranks fifth in frequency of cancer worldwide (Haydon and Hayes, 1995; Sherman, 1995; Chen et al., 1997) . In subSaharan Africa, Southeast Asia and the coastal part of mainland China, the incidence of HCC reaches more than 100/100 000 cases per year (Nagai and Buendia, 1998) . The major risk factors for HCC are hepatitis B virus and hepatitis C virus infection, food contamination with aflatoxin B1 and alcohol abuse. HCC carries a very poor prognosis, and the 5-year survival rate is limited to 25-39% after surgery and causes more than 200 000 mortalities annually (Colombo, 1992) . The development of HCC is a multistep process, during which multiple genetic alterations are accumulated to facilitate cell transformation (Bishop, 1987; Fearon and Vogelstein, 1990; Knudson, 1993; Buendia, 2000; Hanahan and Weinberg, 2000) . Evidences from comprehensive allelotyping by microsatellite assay and comparative genome hybridization have both suggested the inactivation of tumor suppressor genes as well as the activation of proto-oncogenes in HCCs (Hanahan and Weinberg, 2000) . To date, a number of genes, such as p53, pRB, p16
INK4
, Axin1, c-myc, HGF, b-catenin have been reported to be associated with HCC in human and mice (Buendia, 2000) . Many of them are deregulated or mutated; and as a result, affect the cell proliferation or survival. However, these findings are, in most cases, also observed in many other types of cancer. More critical molecules specific for HCC, which will be more informative, remain to be elucidated.
To better understand the critical molecular events involved in the hepatocarcinogenesis, differentiated display (DD) method was employed to identify up-or downregulated genes in HCC specimens compared to normal liver tissue. This approach had led to the cloning and identification of several upregulated genes in HCC by our lab (Chang et al., 2001; Ying et al., 2001a, b) . In this study, we cloned a cDNA sequence, designated as LFIRE-1 (liver fibrinogen-related gene-1), which was a novel alternative splicing form to HFREP-1 (Yamamoto et al., 1993) . We first characterized this liver-specific gene, LFIRE-1/HFREP-1, which was frequently reduced or undetectable in HCC tissues at both RNA and protein level as compared with that in noncancerous counterparts. Its downregulation was significantly associated with the differentiation status of HCC. Several inactivation mutations were accompanied with the loss of heterozygosity in HCC tissues. The deregulation of LFIRE-1/HFREP-1 was related to cell growth and tumorigenicity in vitro and in vivo. These results suggested that the downregulation of LFIRE-1/ HFREP-1 in HCC cells may contribute to hepatocarcinogenesis.
Results
Cloning and characterization of the liver-specific LFIRE-1 cDNA, a novel alternative splicing form to HFREP-1 DD-PCR method was used to identify genes differentially expressed in HCC tissues (Ying et al. , 2001a) . A 294-bp cDNA fragment with a polyadenylation signal was obtained as one of the downregulated genes in four HCC specimens. The subsequent screening of the normal human liver cDNA library, with this fragment as probe, led to the cloning of a 1270-bp full-length cDNA of LFIRE-1 (GenBank Accession no. AF168954), with an open reading frame (ORF) spanning 936 bp (nucleotides 133-1071). The LFIRE-1 cDNA shows 97.6% identity and shares the same ORF with a function-unknown HFREP-1 cDNA (Yamamoto et al., 1993) , except a main discrepancy at 5 0 untranslated region (UTR) (Figure 1a ). The different 5 0 UTRs of LFIRE-1 and HFREP-1 contain a small individual upstream ORF, respectively (Figure 1a) . DNA sequence homology searches in the dbEST databases using the BLAST search program (Altschul et al., 1994) revealed several EST sequences from liver tissue identical to the different 5 0 ends of LFIRE-1 and HFREP-1 cDNAs, respectively, suggesting that both the mRNAs are expressed in liver tissue.
By comparing the cDNA sequence of LFIRE-1 and HFREP-1 with the human genome sequence (genomic clone RP11-156K13, Accession number AC087273) in GenBank nr database, the genomic structure of LFIRE-1 and HFREP-1 was identified. They are located on human chromosome 8p22. The 5 0 UTR of HFREP-1 cDNA is located 109 bp upstream from that of LFIRE-1 in genomic sequence (Figure 1b) . Thus, these two cDNA may be different splicing variants of one gene, designated as LFIRE-1/HFREP-1 in this study. The LFIRE-1/HFREP-1 gene is composed of nine exons and seven introns, spanning a genomic sequence of B31 kb (Figure 1b) . The intron/exon junctions conform to the GT-AG rule, except the exon 1a for HFREP-1 (Figure 1c ).
The size of the LFIRE-1/HFREP-1 transcript and its tissue distribution were estimated in a Northern blot (Figure 1d ). The predicted B1.3 kb LFIRE-1/HFREP-1 transcript was expressed only in human liver, but not in other 11 human tissues, similar to the results previously reported in rat and mouse normal liver (Yamamoto et al., 1993; Yan et al., 2002) . Since the size difference between two alternative splicing variants LFIRE-1 and HFREP-1 is only 60 bp, we used reverse transcription-PCR (RT-PCR) method to amplify these two transcripts from normal liver tissue, respectively. Both the þ RNA isolated from adult tissues, as indicated above each column. The blot was hybridized with 32 P-labeled LFIRE-1/HFREP-1 cDNA fragment encompassing two isoforms (about 950 bp). A transcript of about 1.3 kb was observed only in liver tissue, as indicated by the arrowhead in the right margin. The sizes of RNA markers are indicated at the left in kb. The blot rehybridized with GAPDH probe as a loading control was shown in the lower panel. (e) Expression of LFIRE-1 and HFREP-1 in human normal liver tissue detected by RT-PCR, using the primers specific for LFIRE-1 or HFREP-1, as described in 'Materials and methods'. A 394-bp HFREP-1 and 294-bp LFIRE-1 fragment were visualized on agarose stained with ethidium bromide Growth suppressor activity and downregulation of LFIRE-1/HFREP-1 in HCC J Yan et al paired primers are located in different exons to eliminate the contamination from genomic DNA and the products were verified by DNA sequencing. The result indicated that both transcripts were expressed simultaneously in normal liver cells (Figure 1e ). The ORF of LFIRE-1/HFREP-1 predicts a polypeptide sequence of 312 amino acids corresponding to a calculated molecular weight of 34 kDa and a pI of 5.67. The PROSITE analysis indicates that there is an evolutionarily conserved fibrinogen-related domain (FReD) at its carboxy-terminus from amino acid (aa) 82-302. Potential phosphorylation sites present in LFIRE-1/HFREP-1 include four protein kinase C sites, seven casein kinase II sites and one tyrosine kinase site. Another two tyrosine sulfation sites and two Nmyristoylation sites are also predicted by PROSITE program. BLASTP program reveals that the LFIRE-1/ HFREP-1 protein belongs to the fibrinogen superfamily. The homology region among LFIRE-1/HFREP-1 and other members of this family, such as angiopoietin, tenascin, ficolin and fibrinogen g, is confined to the carboxy-terminus of these proteins over a length of 200B250 aa, with four conserved cysteine residues.
Downregulation of LFIRE-1/HFREP-1 in human HCC cell lines and specimens
To confirm the DD-PCR result, we first analysed the expression of LFIRE-1/HFREP-1 in seven human HCC cell lines by Northern blot and semiquantitative RT-PCR as mentioned above. By Northern blot, the expression of 1.3 kb LFIRE-1/HFREP-1 mRNA was detected only in two well-differentiated HCC cell line (HepG2 and Hep3B), but undetectable in one well-(Huh-7) and four moderately-differentiated (BEL-7402, BEL-7404, SMMC-7721 and QGY-7703) HCC cell lines (Figure2a; Chen et al., 1980; Zhu et al., 1981; Qiang et al., 1997) . Moreover, both the alternative splicing variants were expressed in HepG2 and Hep3B (Figure 2b ). The expression of 34 kDa protein of LFIRE-1/HFREP-1 in HepG2 and Hep3B cells, but not in other five HCC cell lines, was also confirmed by Western blot (Figure 2c ). The results demonstrated that the expression of LFIRE-1/HFREP-1 was lost in most of the HCC cell lines.
To investigate the expression pattern of LFIRE-1 and HFREP-1 in HCC specimens, we performed Northern Representative RT-PCR analysis of expression of LFIRE-1 and HFREP-1 in 11 pairs of HCC specimens, using the primers specific for LFIRE-1 or HFREP-1, respectively. b-Actin was determined as a control for RNA integrity. (f) Representative Western blot analysis of expression of LFIRE-1/HFREP-1 protein in the same 11 pairs of HCC specimens as those in RT-PCR analysis. Actin was used as loading control. Cases with downregulated LFIRE-1/HFREP-1 in HCC specimens were indicated with an asterisk analysis in 34 paired HCC. The result indicated that the LFIRE-1/HFREP-1 expression was downregulated or undetectable in 21 out of 34 cases of HCC specimens compared with their adjacent normal liver specimens (Figure 2d ). Semiquantitative RT-PCR in 22 paired HCC specimens showed that both of these two alternative splicing variants are concurrently downregulated or undetectable in the same 10 out of 22 HCC specimens compared with those in adjacent normal liver tissues (Figure 2e ). Moreover, we also found the reduced LFIRE-1/HFREP-1 protein in six out of 15 paired HCCs, which has been analysed at RNA level ( Figure 2f ). The result indicated the expression of LFIRE-1/HFREP-1 was downregulated in 58.3% (28/48) of HCC specimens.
Then, we examined the LFIRE-1/HFREP-1 expression in a large scale of specimens by immunohistochemical staining (IHC; Figure 3 and Table 1 ). In total, nine normal liver tissues and 76 paired HCC specimens were tested. We found that all of the nine normal liver tissues and 76 noncancerous liver tissues adjacent to HCCs expressed high level of LFIRE-1/HFREP-1 protein, which was mainly localized in the cytoplasmic compartments of the hepatocytes (Figure3a and inset). Compared to the adjacent noncancerous liver area ( Figure  3b Table 1 , we found that the proportion of specimens lacking LFIRE-1/HFREP-1 staining increased in the well-differentiated (WD) HCCs (11/23, 47.8%; Po0.05, normal vs WD). A higher proportion of specimens with undetectable LFIRE-1/ HFREP-1 expression was found in moderately differentiated (MD) HCC (24/38, 63.2%; Po0.005, normal vs MD) and poorly differentiated (PD) HCCs (12/15, 80%; Po0.005, normal vs PD). Moreover, its downregulated expression appeared frequently in poorly-differentiated HCCs when compared with welldifferentiated HCCs (Po0.05, WD vs PD). The downregulation of LFIRE-1/HFREP-1 in HCC was not correlated significantly with sex, age and hepatitis viruses infection of patients (w 2 test, data not shown). Therefore, our data indicated that the downregulation of LFIRE-1/ HFREP-1 is significantly associated with hepatocarcinogenesis and its differentiation status.
Genetic alteration of LFIRE-1/HFREP-1 in HCC specimens
Since LFIRE-1/HFREP-1 is located at human chromosome 8p22, a region of high frequency LOH in HCCs, three polymorphic microsatellites markers, D8S261, D8S254 and D8S1731, around LFIRE-1/HFREP-1 locus were chosen to survey the allelic status of this locus in 45 cases of HCC specimens. Overall, allelic loss of LFIRE-1/HFREP-1 on 8p22 was observed in 24 of 45 patients ( Figure 4a ). In three cases (case 7, 10, 63), all loci examined were noninformative (homozygous). Considering the informative tumors only, a markedly high rate of allelic loss (57.1%, 24/42) was found for markers encompassing the LFIRE-1/HFREP-1 locus on chromosome 8p22.
Furthermore, we analysed the LFIRE-1/HFREP-1 mRNA expression in 26 cases (case nos. 1-11 and 15-29, Figure 4a ) of HCC specimens to explore the possible correlation of mRNA expression level with the allelic loss of LFIRE-1/HFREP-1. As shown in Figure 4a -c, LOH occurred in 17 out of 26 HCC specimens and downregulated LFIRE-1/HFREP-1 expression c PD, poorly-differentiated HCC. We categorized the specimens with different intensity of positive signal into the group positive before the statistic analysis was performed. The w presented in 70.6% (12/17) of HCCs with LOH. However, its downregulation appeared only in one out of nine HCCs without LOH (Po0.01). This result suggested that allelic loss may contribute to the downregulation of LFIRE-1/HFREP-1.
Next, we examined all exons of the LFIRE-1/HFREP-1 gene in 45 HCCs for mutation analysis by PCR-SSCP and direct sequencing. We detected three tumor-specific mutations in three HCC tissues (Figure 4d ). Case 46 exhibited 1-bp insertion in codon 42 of LFIRE-1/ HFREP-1, resulting in a frameshift that is predicted to produce a 58-aa truncated peptide without the FReD. The other two mutations happened on the conserved fibrinogen domain of LFIRE-1/HFREP-1. Case 7 showed a T to G transversion in codon 83, leading to the substitution of the conserved cysteine to glycine (C83G) (Figure 4d ). Another T to C transition in codon 137 accompanied by loss of the wild-type allele was detected in the case 53, resulting in the replacement of conserved tryptophan by arginine (W137R) (Figure 4d ). All of mutations detected herein change the integrity of the FReD in LFIRE-1/HFREP-1 protein.
Suppression of endogenous LFIRE-1/HFREP-1 enhances HCC cell growth
To examine whether LFIRE-1/HFREP-1 might affect the growth of HCC cells or not, an antisense approach was employed in this study. By direct sequencing of RT-PCR product covering the whole ORF, we found that both of HepG2 and Hep3B cell lines expressed wild-type LFIRE-1/HFREP-1 (data not shown). Next, we designed three antisense oligonucleotides (AS-ODNs), that is, AS-1 is intended to represent a region encompassing the translational start site, while AS-2 and AS-3 are designated to the ORF and 3 0 UTR region. The corresponding sense sequences (S-1-S-3) and missense sequence (MS-1-MS-3) were selected as controls. HepG2 cells were seeded to examine whether AS-ODNs function well in eliminating target protein in a sequencespecific manner. As shown in Figure 5a , we found that all of AS-ODNs can effectively reduce the endogenous level of LFIRE-1/HFREP-1 protein. In contrast, no significant influence was observed on LFIRE-1/ HFREP-1 protein with the corresponding S-or MSODNs. In cell growth assay, the number of HepG2 cells In case 7, the mutation T-to-G results in a Cys -Gly change at aa 83. The T insertion in case 46 resulted in frame shift and truncated protein product. In case 53, the mutation T-to-C results in a TrpArg change in aa 137
Growth suppressor activity and downregulation of LFIRE-1/HFREP-1 in HCC J Yan et al treated with three AS-ODNs (AS-1, AS-2 and AS-3) showed 1.3-to 1.4-fold greater than that of control HepG2 cells treated with the corresponding S-ODNs and MS-ODNs after 6-day treatment (Figure 5b-d) . In soft agar assay, HepG2 cells treated with AS-ODNs showed significantly increase of colony number in soft agar, compared with HepG2 cells treated with S-ODNs or MS-ODNs. The data indicated the AS-ODNs reduced the expression of LFIRE-1/HFREP-1 and stimulated the HepG2 cell anchorage-dependent andindependent growth in a gene-specific manner.
Introduction of wild-type, but not mutant, LFIRE-1/ HFREP-1 inhibited the growth and tumorigenecity of HCC cells in vitro and in vivo Recombinant plasmids containing the full ORF of wildtype LFIRE-1/HFREP-1 or two missense mutants (C83G and W137R) were transfected into BEL-7402 and BEL-7404 cells, which do not express endogenous LFIRE-1/HFREP-1. After 21-day G418 selection, we found a consistent reduction (83% in BEL-7402 and 73% in BEL-7404, Figure 6a ,b) of colony number in wild-type LFIRE-1/HFREP-1 construct-transfected cells as compared with the control vector. By contrast, two mutants C83G and W137R had lost most of this colony suppressive activity. The numbers of colonies were also consistently reduced after transfection with wild-type LFIRE-1/HFREP-1 into other HCC lines (66.7% in QGY-7703, 74.1% in Huh-7 and 62% in SMMC-7721, data not shown). The efficiency of each transfection was monitored by GFP cotransfection in other wells after 48 h. All of the transfections displayed a similar efficiency.
Meanwhile, several G418-resistant clones from BEL-7402 cell transfectants were randomly selected for further analysis to characterize the function of LFIRE-1/HFREP-1 in HCC cells. Figure 7a showed the expression of LFIRE-1/HFREP-1 in all three wild-type LFIRE-1/HFERP-1 transfectant clones (L1, L2 and L3), two C83G transfectant clones (C1, C2) and two W137R transfectant clones (W1, W2), but lower than that in normal liver tissue (Figure 7a ). No signal was detected in the empty vector transfectant (V). From day 2 onwards, all of three wild-type LFIRE-1/HFERP-1 transfectants L1, L2, L3 grew at a reduced rate compared to vector control and mutant transfectants (Figure 7b ). Compared with the vector transfectant, the wild-type LFIRE-1/HFERP-1 transfectants L1, L2 and L3 showed a marked decrease of anchorage-independent growth potential in soft-agar (Figure 7c) . However, the mutated LFIRE-1/HFERP-1 lost the suppressor activities in C1, C2 and W1, W2 transfectant cells and retained the capacity of anchorage-independent growth in soft-agar (Figure 7c ).
The LFIRE-1/HFREP-1-transfected cells and the vector transfectant cells were further examined for tumorigenicity by injecting cells subcutaneously into BALB/c nu/nu mice. The results indicated that tumorigenicity was significantly reduced in all of the three wild-type LFIRE-1/HFREP-1 transfectants compared with the vector and mutant transfectants (Figure 7d) . Similar results were also obtained in wild-type LFIRE-1/ HFREP-1-transfected BEL-7404 cells (data not shown). These data implied that LFIRE-1/HFREP-1 played a suppressor role to reverse the malignant growth potential of HCC cells in vitro and in vivo.
Discussion
During hepatocarcinogenesis, various genetic and epigenetic alterations accumulate to facilitate the cell transformation and enhance the aggressive behaviors. Although, a number of cellular genes have been identified to be involved in hepatocarcinogenesis, little is reported uniquely and directly responsible for HCC. Therefore, it is vital to identify more proteins specifically related to hepatocarcinogenesis, which may expand our understanding of this disease and develop new targets for therapy and indicator of diagnosis.
Here, we reported that the human LFIRE-1/HFREP-1 was a liver-specific gene and frequently downregulated or lost in HCCs at both mRNA (by semiquantitative RT-PCR and Northern blot) and protein (by Western Growth suppressor activity and downregulation of LFIRE-1/HFREP-1 in HCC J Yan et al blot and IHC) levels, compared to their adjacent normal liver tissues. The LFIRE-1/HFREP-1 expression level was found to be obviously associated with the differentiation status of the tumors. The specific expression pattern of the LFIRE-1/HFREP-1 gene in normal liver, the downregulation in HCCs and its structural homology to fibrinogen superfamily suggest that the LFIRE-1/ HFREP-1 might be a differentiation marker and play an important role in the development and physiological function of liver. The abnormal alterations on genetic and epigenetic characteristics of LFIRE-1/HFREP-1 will be responsible to the hepatocarcinogenesis process. LFIRE-1/HFREP-1 is located on human chromosome 8p, where frequent and cumulative allelic loss is correlated with a more aggressive tumor behavior in HCC and increased risk of disease recurrence (Emi et al., 1993; Kuroki et al., 1995; Qin et al., 1999; Chan et al., 2002) . Our LOH data revealed that 57.1% of informative HCCs studied had allelic loss at the LFIRE-1/HFREP-1 locus, which is in agreement with those reported in previous studies on HCC (Pineau et al., 1999; Chan et al., 2002) . When the LOH data were compared with the LFIRE-1/HFREP-1 mRNA expression, we found the possibility that downregulation of LFIRE-1/HFREP-1 might be caused by an allelic loss of LFIRE-1/HFREP-1 gene.
We detected three mutations in 45 HCC specimens indicating one case of frameshift and two cases of replacements of conserved amino acids in LFIRE-1/ HFREP-1 molecules. All of three mutations may affect the integrity of FReD in LFIRE-1/HFREP-1, which is regarded to serve as a binding site for other proteins (Farrell and Thiagarajan, 1994; Procopio et al., 1999) . The mutants seem to be incapable of playing the expected role in growth regulation in cancer cells as demonstrated in function assay. These data indicated that LFIRE-1/HFREP-1 fit the Knudson's two-hit hypothesis for tumor suppressor gene.
We also tested the epigenetic modification of LFIRE-1/HFREP-1 by treating LFIRE-1/HFREP-1-deficient HCC cell lines with 5 0 azaC. However, we did not detect the restoration of this gene, suggesting that the methylation might not be the main mechanism for inactivation of LFIRE-1/HFREP-1 (data not shown). Other causes such as the regulation alterations at transcription and post-transcription level or other epigenetic modification should also be addressed in future study (Jones and Laird 1999; Feinberg 2001) .
Our previous study on mouse orthologue of the LFIRE-1/HFREP-1 gene, MFREP-1, revealed that MFREP-1 is upregulated in mouse partial hepatectomy (PHx) model (Yan et al., 2002) . MFREP-1 is associated with liver cell growth because it is upregulated in 2 h after PHx, which needs de novo protein synthesis. The enhanced expression remains high even in the late phase of liver regeneration (day 3-14 after PHx), just like the expression kinetics of some well-known genes in PHx, such as TGFb1 and C/EBPa. The data implied the potential function of MFREP-1 in growth regulation of normal liver cells. The critical importance of LFIRE-1/HFREP-1 gene in the regulation of HCC cells growth was proved by two approaches interfering the expression of the gene in cancer cells. Strong evidence is that the blocking of the expression and function of endogenous LFIRE-1/ HFREP-1 by AS-ODNs treatment results in a promoted anchorage-dependent and -independent growth of cancer cells, while restoration of exogenous wild-type LFIRE-1/HFREP-1, but not two mutants and vector control, reduces the growth rate, colony formation and tumorigenicity of HCC cells. We noted that these mutant LFIRE-1/HFREP-1 proteins differ in only a single amino acid from the wild-type sequence and were expressed at a similar protein levels but were not cytotoxic to HCC cells compared with wild-type LFIRE-1/HFREP-1. It is deemed that the LFIRE-1/ HFREP-1 gene functions in the regulation of liver cancer cell growth and differentiation in a negative fashion.
Genome-wide analysis has revealed that 40-60% of human genes have alternative splice forms (Modrek and . The alternative splicing at 5 0 UTR may affect the transcription or translation efficiency or RNA stability (Mironov et al., 1999) . The LFIRE-1/HFREP-1 gene contains two alternative splicing forms, with discrepancy at 5 0 UTR. There exist different uORFs in 5 0 UTR of these two transcripts. Since the expression analysis revealed that two transcripts of LFIRE-1/ HFREP-1 were concurrently downregulated in HCCs, the possible correlation of its alternative splicing with the physiological function or pathological action remains to be clarified.
The HFREP-1 gene was initially detected as elevated in only one HCC specimens (Yamamoto et al., 1993) . This occasional reversal of expression pattern for a putative tumor suppressor gene has also been observed in other well-recognized tumor suppressor genes and may be related to alterations upstream of the target sequence. For example, occasional upregulation of the BAX and p21 tumor suppressor genes in thyroid cancer is associated with the dys-regulation of wild-type p53 (Hermann et al., 2001 ).
In conclusion, we describe here the characterization of liver-specific gene LFIRE-1/HFREP-1, which is frequently downregulated in HCCs. Its frequent downregulation is associated with tumor differentiation status. Genetic alterations and functional assays suggested that LFIRE-1/HFREP-1 plays a role as growth suppressor in human HCC. Therefore, it will be a potential diagnosis indicator and target for pharmaceutical intervention against HCC.
Materials and methods

Cell lines, primary HCC and adjacent tissues
A number of human HCC cell lines (BEL-7402, BEL-7404, SMMC-7721, QGY-7703, HepG2) were obtained from the Cell Bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Hep3B was obtained from Shanghai Liver Cancer Institute (Shanghai, China) and Huh-7 was obtained from Eastern Hepatobiliary Surgical Hospital (Shanghai, China). All of the cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Life Technologies Inc., Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS; Life Technologies Inc., Rockville, MD, USA) at 371C in 5% CO 2 . The normal liver tissues, primary HCC specimens and its adjacent noncancerous liver tissues were obtained from Eastern Hepatobiliary Surgery Hospital and Changzheng Hospital (Shanghai, China). All tissues were placed in liquid nitrogen immediately after surgical resection.
Isolation of cDNA for LFIRE-1
The SUPERSCRIPT human liver cDNA library (Life Technologies Inc.) contained 1 Â 10 7 independent clones and was amplified once. The library was screened using the cloned PCR fragment as probe to isolate the full-length cDNA for LFIRE-1/HFREP-1 and the positive clones were identified by Southern blot as in our previous description (Ying et al. 2001b) . The longest cDNA insert from one of the positive colonies was sequenced. The sequence homology to published database was analysed with the BLAST program at an internet site of National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/blast/blast.cgi).
Northern blot analysis
Total RNAs were isolated from HCC cell lines and frozen HCC specimens by Trizol (Life Technologies), according to the manufacture's instruction and kept at À701C until used. Northern blot assay was performed as described previously (Ying et al., 2001b) . Briefly, 30 mg of total RNAs were separated on a 1.0% formaldehyde/agarose gel by electrophoresis, transferred to Hybond XL (Amersham) nylon filters and hybridized with a-32 P-labeled cDNA for LFIRE-1/ HFREP-1 (B900 bp, encompassing the ORF) using Prime-aGene system (Promega, Madison, WI, USA). The multiple tissue poly(A) þ RNAs blot was kindly provided by Dr Dexi Zhu (Nanjing University, Nanjing, China). The blot contained 2 mg poly(A) þ RNA each of 12 kinds of human tissues separated in 1.0% formaldehyde/agarose gel. The expression level of mRNA for LFIRE-1/HFREP-1 was normalized with 18S rRNA or GAPDH as internal standard and analysed by Phosphor Imager (FLA 2000, Fujifilm, Japan) .
Semiquantitative RT-PCR
In all, 2 mg of RNAs were reverse-transcribed by M-MLV (Life Technologies) using random primers according to the manual. Gene expression was measured at the exponential range of amplification of the PCR for LFIRE-1/HFREP-1 and the normalization control gene b-actin. To confirm product specificity, PCR products were subjected to cDNA sequencing. Specific primers used for LFIRE-1 transcript were forward primer (5 0 -AGTCTGCTTCTGCTACTTGG-3 0 , nucleotide (nt): 24-43) and reverse primer (5 0 -ACTGGACTT-CATTCTCCTGC-3 0 , nt: 297-316). The specific primers for HFREP-1 transcript were forward primer (5 0 -GAGTGTCTG-GATGGAACCTGA-3 0 , nt: 11-31, number in HFREP-1) and reverse primer (5 0 -GAAAATTCTGCTGGGCTCTGG-3 0 , nt: 384-404, number in HFREP-1). PCR was performed in a Programmed Thermal Controller (PTC-100, MJ Research Inc. Watertown, MA, USA). Initial denaturation was performed at 951C for 5 min, followed by 28 cycles of 30 s at 941C, 1 min at 58/621C and 1 min at 721C, with a final extension at 721C for 10 min. The PCR products were separated in 1.5% agarose gel with ethidium bromide staining.
Preparation of polyantibody against LFIRE-1/HFREP-1
A cDNA fragment encoding for the LFIRE-1/HFREP-1 (amino acid 22-213) was subcloned into the pGEX5X-2 vector (Amersham, Little Calfont, UK). The construct was sequenced to check for mutations and used to transform BL-21 Escherichia coli. The recombinant protein was induced by 1 mM isopropyl-b-D-thiogalactopyranoside and purified by Glutathione-Sepharose 4B (Amersham). The samples containing purified LFIRE-1/HFREP-1-GST fusion protein were examined by electrophoresis on 15% SDS-PAGE and stored in aliquots at À701C. For preparation of polyantibody, 2 mg of the purified LFIRE-1/HFREP-1-GST fusion protein were emulsified with complete Freund's adjuvant (Life Technologies) and subcutaneously injected into two New Zealand rabbits. Following the first immunization, 1, 0.5 and 0.25 was used to reimmunize the rabbits at 2-week intervals. Antibody valence and specificity was determined by Western blotting. Anti-LFIRE-1/HFREP-1 IgG was purified by recombinant protein G agarose (Life Technologies), according to the manufacturer's manual.
Western blot assay
The cells were washed with ice-cold phosphate-buffered saline and lysed in a buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 10 mM sodium pyrophosphate, 40 mM sodium orthovanadate, 1 mg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, 10% glycerol and 1% Triton X-100 on ice for 30 min. The lysates were centrifugated at 10 000 r.p.m. for 10 min. The supernatant were separated by 15% SDS-PAGE, electrotransferred to PVDF membranes for hybridization with purified anit-LFIRE-1/HFREP-1 antibodies. The bands were visualized by ECL method (Amersham).
Immunohistochemistry
Surgical specimens including HCC tissues and their adjacent normal liver tissues were fixed in 10% neutral formalin, dehydrated in graded alcohol and embedded in paraffin. Paraffin sections (4-6 ım) were subjected to immunoperoxidase staining with LFIRE-1/HFREP-1 antibody. In brief, the paraffin-embedded tissues were microwaved for 5 min for antigen retrieval. Then, all samples were incubated with 3% H 2 O 2 in methanol solution for 12 min at room temperature to block endogenous peroxidases. The sections were then incubated with 10% goat serum to reduce nonspecific binding. Afterwards, the sections were sequentially incubated with anti-LFIRE-1/HFREP-1 polyclonal antibody (1 : 100), biotinylated goat anti-rabbit IgG and avidin-biotin complex. Then, the sections were incubated with 3,3 0 -diaminobenzidine tetrahydrochloride in 0.03% H 2 O 2 and 50 mM Tris-HCl (pH7.4) for detection. Finally, the sections were counterstained with hematoxylin and examined under a light microscope. Sections incubated in rabbit serum instead of the corresponding primary antibody were used for comparison as negative control.
LOH analysis and mutation screening
Primers for the three polymorphic markers (D8S261, D8S254 and D8S1731) were synthesized according to the public primer sequences in internet Genome Database. In PCR-SSCP assay, primers for eight exons are located in the intron sequence adjacent to the corresponding exon except the reverse primer of amplicon 8 in the 3 0 UTR. The primers for mutation detection are: 1aF: 5 0 -CTTCTCTTTTAGCTTTCTTTCAG- Denatuaration at 951C for 5 min was followed by 30-35 cycles of 1 min at 941C, 1 min at annealing temperature (between 55 and 621C) and 1 min at 721C, with a final extension of 10 min, 721C for 1 min. PCR products for LOH analysis were subjected to electrophoresis on a denaturating 6% PAG and autoradiography. Intensity or signal ratio difference of 35% or more between HCC and its adjacent normal tissue were considered sufficient for LOH assignment. All the PCR products for SSCP assay were loaded onto the 8% PAG with 10% glycerol at room temperature or without 10% glycerol at 41C. The samples with aberrant bands were reamplified and PCR products were purified on a QIAquick spin column (QIAGEN) and sequenced directly without subcloning.
Site-directed mutagenesis
Site-directed mutants of LFIRE-1/HFREP-1 were prepared by in vitro recombination and mutagenesis by overlap extension PCR method (Ho et al., 1989) . The primers for C83G were C83GF (5 0 -CAAGAGGCAGTATGCAGATGGTTCAGA-GATTTTCAA-3 0 ) and C83GR (5 0 -TTGAAAATCTCT-GAACCATCTGCATACTCCTCTTG-3 0 ). The primers for W137R were W137RF (5 0 -AAAACTTTAACAGAGGACG-GAAAGACTAT-3 0 ) and W137RR (5 0 -ATAGTCTTT-CCGTCCTCTGTTAAAGTTTT-3 0 ). The underlined portions include the mismatch. The flanking primers are LHF: 5 0 -GGGGGATCCGGGAACATGGCAAAGGTGT-3 0 and LHR: 5 0 -GGGGAAGCTTAATTACATTTGGAATAAA-3 0 . Briefly, in two separate PCR amplifications, double-stranded fragments are generated and subsequently fused in PCR reaction 3. PCR reaction 1 uses a flanking primer LHF and mutagenic primer C83GR or W137RR, respectively. In PCR reaction 2, another flanking primer LHR and mutagenic primer C83GF or W137RF are used to generate the second fragment, respectively. The reaction conditions were a 2-min incubation at 941C followed by 28 cycles of 1 min at 941C, 45 s at 601C and 1 min at 721C. Each PCR subfragments were purified, mixed and used as a template in a third PCR reaction with only the flanking primers. The conditions for the PCR extension were a 2-min incubation at 941C, followed by five cycles of 1 min at 941C, 1 min at 551C and 1 min at 721C. Then the PCR reaction incubation was changed to 25 cycles of 1 min at 941C, 1 min at 621C, and 1 min at 721C. The PCR product was subcloned into the pcDNA3 vector (Invitrogen, Inc., Carlsbad, CA, USA). All mutant LFIRE-1/HFREP-1 constructs were sequenced to ensure that only the intended alterations were introduced by the mutagenesis.
Effect of antisense oligodeoxynucleotides (AS-ODNs) on cell growth
Phosphorothioate ODNs targeted against LFIRE-1/HFREP-1 mRNA were synthesized and purified by Sangon (Shanghai, China) . In this study, we used AS-ODNs against three different regions of LFIRE-1/ HFREP-1: AS-1: 5 0 -CACCT-TTGCCATGTTCCCCC-3 0 (nt 125-144); AS-2: 5 0 -TGAC-CTGTTGCTGTTTGACC-3 0 (nt 261-280); AS-3: 5 0 -GTAA-CAAAGGCAAGTGAG-3 0 (nt 1194-1211). Missense (MS) and sense (S) ODNs corresponding to each AS-ODNs were used as controls. MS-1: 5 0 -CACCTTTGCGATCTTGCCCC-3 0 ; MS-2: 5 0 -TGACGTGTTCCTGTTTCACC-3 0 ; MS-3: 5 0 -GTAACAAACCCAAGTGAC-3 0 . S-1: 5 0 -GGGGGAACAT-GGCAAAGGTG-3 0 ; S-2: 5 0 -GGTCAAACAGCAACAGGT-CA-3 0 ; S-3: 5 0 -CTCACTTGCCTTTGTTAC-3 0 . The method for antisense assay was performed as described previously (Ying et al., 2001a) . In brief, cells were seeded in 24-well microtiter plates (Corning Inc., Corning, NY, USA) at approximately 1 Â 10 4 cells per well. After cells adhering to the plate overnight, the medium was replaced with fresh medium that contained 5 mmol/l AS-ODNs. The fresh medium containing AS-ODNs at the same concentration was replaced at 2-day intervals. Viable cells were counted after 2, 4 and 6 days.
Transfection and colony formation assay
Two human HCC cell lines, BEL-7402 and BEL-7404 cells, were seeded at a density of 2 Â 10 5 cells/well in six-well plates and allowed to attach overnight. Cells were transfected with 1 mg of wild-type or two mutant (C83G and W137R) LFIRE-1/ HFREP-1 expression construct and pcDNA3 vector, respectively, with FuGene 6 reagent (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instruction. Meanwhile, we cotransfected 1 mg of wild-type or mutant constructs or pcDNA3 with 0.5 mg pEGFP-N1 into the cells in other wells, followed by 48 h culture in DMEM with 10% FCS to measure the transfection efficiency under epifluorescence microscope. After G418 (400 mg/ml) selection for 3 weeks, positive colonies were fixed with methanol and stained with Giemsa for enumeration. Each transfection experiment was performed in triplicate and repeat twice.
MTT assay
Cells harboring wild-type LFIRE-1/HFREP-1, C83G, W137R or empty vector were isolated and screened by Western blot assay as described above. Cells were seeded on a 96-well plate (Corning) at 1 Â 10 4 cells/well in DMEM containing 10% FCS. After 2, 4, 6 and 8 days, the number of cells was quantitated by MTT (Sigma Inc., St Louis, MO, USA) assay as described previously (Ying et al., 2001a) .
Soft agar assay
We plated aliquots of logarithmically growing cells (2 Â 10 3 cells) as a single-cell suspension in 0.35%. agarose in DMEM containing 10% FCS and gelled at 41C for 30 min over a previously gelled layer of 0.6% agarose in the same complete media in six-well dishes. After 20-day incubation, 1 ml of 0.5 mg/ml p-iodonitrotetrazolium violet (Sigma) was added to each well and incubated overnight. Colonies with a diameter greater than 100 mm were counted. The experiment was performed in triplicate.
Tumor studies
We investigated the in vivo tumorigenicity potential of wild type and two mutant LFIRE-1/HFREP-1 transfectant clones or control cells in nude mice. The logarithmically growing cells were trypsinized and resuspended in D'Hanks solution, and 5 Â 10 6 cells in 0.2 ml were injected subcutaneously into the left flank of 4-week-age female BALB/c nu/nu mice. Experimental and control groups had at least three mice each. The volume of tumor was calculated as volume ¼ (length Â width 2 ) Â 0.5.
